Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Prolight Diagnostics ABNGM:PRLD +2.29%31 PB Ratio is 1.35 as of Aug. 02, 2026. GuruFocus rates NGM:PRLD with a GF Score™ of 31/100. The stock has 1 warning sign investors should review. Among 788 Medical Devices & Instruments companies, Prolight Diagnostics AB ranks better than 68.15% on this metric.
The historical rank and industry rank for Prolight Diagnostics AB's PB Ratio or its related term are showing as below:
NGM:PRLD'
s PB Ratio Range Over the Past 10 Years
Min: 0 Med: 0 Max: 1.41
Current: 1.35
During the past 10 years, Prolight Diagnostics AB's highest PB Ratio was 1.41. The lowest was 0.00. And the median was 0.00.
NGM:PRLD's PB Ratio is ranked better than 68.15% of 788
companies
in the Medical Devices & Instruments industry
Industry Median: 2.06
vs NGM:PRLD: 1.35
During the past 12 months, Prolight Diagnostics AB's average Book Value Per Share Growth Rate was -15.90% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -40.50% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -35.20% per year.
During the past 10 years, the highest 3-Year average Book Value Per Share Growth Rate of Prolight Diagnostics AB was 29.00% per year. The lowest was -42.90% per year. And the median was -3.00% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Prolight Diagnostics AB's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Prolight Diagnostics AB PB Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Prolight Diagnostics AB's PB Ratio distribution charts can be found below:
* The bar in red indicates where Prolight Diagnostics AB's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Prolight Diagnostics AB (NGM:PRLD) has a PB Ratio of 1.35 as of Aug. 02, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Prolight Diagnostics AB and its competitors. According to the industry distribution chart, Prolight Diagnostics AB ranks #251 out of 788 companies in the Medical Devices & Instruments industry, placing it in the top 31.9%.
Is Prolight Diagnostics AB's PB Ratio too high?
Prolight Diagnostics AB's current PB Ratio is 1.35. The Medical Devices & Instruments industry median PB Ratio is 2.06. Prolight Diagnostics AB's value of 1.35 is 34.5% below this industry median. Based on the distribution chart, Prolight Diagnostics AB ranks #251 out of 788 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Prolight Diagnostics AB has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Prolight Diagnostics AB's PB Ratio compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Prolight Diagnostics AB ranks #251 out of 788 companies for PB Ratio. This puts Prolight Diagnostics AB in the upper half of its industry. The industry median PB Ratio is 2.06. Prolight Diagnostics AB's value of 1.35 is 34.5% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Medical Devices & Instruments company?
The median PB Ratio among Medical Devices & Instruments companies is 2.06, based on 788 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Prolight Diagnostics AB's current PB Ratio of 1.35 is 34.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Prolight Diagnostics AB and its competitors. For the Medical Devices & Instruments industry, the median PB Ratio is 2.06 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Prolight Diagnostics AB's current PB Ratio is 1.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prolight Diagnostics AB stock overvalued right now?
Prolight Diagnostics AB (NGM:PRLD) has a current PB Ratio of 1.35. The current PB Ratio is 1.35 and 34.5% below the Medical Devices & Instruments industry median of 2.06. Prolight Diagnostics AB's overall GF Score™ is 31/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Prolight Diagnostics AB (NGM:PRLD), the current PB Ratio is 1.35 as of Aug. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Prolight Diagnostics AB along with its subsidiaries, develops Point-of-Care (POC) systems, which are small, portable instruments and disposable cartridges for performing in-vitro diagnostic (IVD) tests from a drop of blood. Its product portfolio includes Psyros, a digital POC technology, and Microflex.
31GF Score
Get the complete analysis for NGM:PRLD
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NGM:PRLD has been successfully added to your 
